Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy.

Potiron V, Clément-Colmou K, Jouglar E, Pietri M, Chiavassa S, Delpon G, Paris F, Supiot S.

Cancer Lett. 2019 Aug 10;457:1-9. doi: 10.1016/j.canlet.2019.05.005. Epub 2019 May 9.

PMID:
31078733
2.

Reoxygenation during radiotherapy in intermediate-risk prostate cancer.

Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D.

Radiother Oncol. 2019 Apr;133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12.

PMID:
30935573
3.

Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study.

Supiot S, Rousseau C, Dore M, Cheze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D.

Oncotarget. 2018 Jan 13;9(11):10005-10015. doi: 10.18632/oncotarget.24234. eCollection 2018 Feb 9.

4.

A new tissue segmentation method to calculate 3D dose in small animal radiation therapy.

Noblet C, Delpon G, Supiot S, Potiron V, Paris F, Chiavassa S.

Radiat Oncol. 2018 Feb 26;13(1):32. doi: 10.1186/s13014-018-0971-8.

5.

Optimizing radiotherapy protocols using computer automata to model tumour cell death as a function of oxygen diffusion processes.

Paul-Gilloteaux P, Potiron V, Delpon G, Supiot S, Chiavassa S, Paris F, Costes SV.

Sci Rep. 2017 May 23;7(1):2280. doi: 10.1038/s41598-017-01757-6.

6.

Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer.

Potiron VA, Abderrahmani R, Clément-Colmou K, Marionneau-Lambot S, Oullier T, Paris F, Supiot S.

PLoS One. 2013 Dec 31;8(12):e84076. doi: 10.1371/journal.pone.0084076. eCollection 2013.

7.

Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA.

Cancer Res. 2013 Dec 1;73(23):7111-21. doi: 10.1158/0008-5472.CAN-13-1755. Epub 2013 Oct 11. Erratum in: Cancer Res. 2014 Jan 15;74(2):637.

8.

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

Potiron VA, Abderrahmani R, Giang E, Chiavassa S, Di Tomaso E, Maira SM, Paris F, Supiot S.

Radiother Oncol. 2013 Jan;106(1):138-46. doi: 10.1016/j.radonc.2012.11.014. Epub 2013 Jan 12. Erratum in: Radiother Oncol. 2013 May;107(2):263. Abderrhamani, Rym [corrected to Abderrahmani, Rym].

PMID:
23321494
9.

ZEB1-responsive genes in non-small cell lung cancer.

Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA.

Cancer Lett. 2011 Jan 1;300(1):66-78. doi: 10.1016/j.canlet.2010.09.007. Epub 2010 Oct 25.

10.

Guidance molecules in lung cancer.

Nasarre P, Potiron V, Drabkin H, Roche J.

Cell Adh Migr. 2010 Jan-Mar;4(1):130-45. Epub 2010 Jan 7. Review.

11.

ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.

Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J.

Neoplasia. 2009 Feb;11(2):157-66.

12.

Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?

Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J.

Br J Cancer. 2008 Oct 7;99(7):1153-60. doi: 10.1038/sj.bjc.6604641. Epub 2008 Sep 9.

13.

Semaphorins and their receptors in lung cancer.

Potiron VA, Roche J, Drabkin HA.

Cancer Lett. 2009 Jan 8;273(1):1-14. doi: 10.1016/j.canlet.2008.05.032. Epub 2008 Jul 14. Review.

14.

Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.

Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA.

Cancer Res. 2007 Sep 15;67(18):8708-15.

15.

Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.

Loudni L, Roche J, Potiron V, Clarhaut J, Bachmann C, Gesson JP, Tranoy-Opalinski I.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4819-23. Epub 2007 Jun 27.

PMID:
17624773
16.

Semaphorin signaling in the immune system.

Potiron V, Nasarre P, Roche J, Healy C, Boumsell L.

Adv Exp Med Biol. 2007;600:132-44. Review.

PMID:
17607952
17.

Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene.

Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J.

Biochim Biophys Acta. 2005 Jul 25;1730(1):66-76.

PMID:
16005989
18.

Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells.

Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J.

Neoplasia. 2005 May;7(5):457-65.

19.

Class 3 semaphorin signaling: the end of a dogma.

Potiron V, Roche J.

Sci STKE. 2005 May 24;2005(285):pe24. Review.

PMID:
15914725

Supplemental Content

Loading ...
Support Center